Aridis Pharmaceuticals, Inc. (ARDS)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2022 | -30.74 Million USD | 27.27% |
| 2021 | -42.28 Million USD | -92.9% |
| 2020 | -21.91 Million USD | 24.38% |
| 2019 | -28.98 Million USD | -31.13% |
| 2018 | -22.1 Million USD | 10.35% |
| 2017 | -24.65 Million USD | -192.76% |
| 2016 | -8.42 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q3 | -83 Thousand USD | -100.68% |
| 2023 Q2 | 12.14 Million USD | 265.4% |
| 2023 Q1 | -7.34 Million USD | -37.13% |
| 2022 Q1 | -8.1 Million USD | 20.72% |
| 2022 FY | -30.74 Million USD | 27.27% |
| 2022 Q3 | -9.06 Million USD | -10.28% |
| 2022 Q2 | -8.22 Million USD | -1.39% |
| 2022 Q4 | -5.35 Million USD | 40.94% |
| 2021 FY | -42.28 Million USD | -92.9% |
| 2021 Q2 | -5.49 Million USD | 20.33% |
| 2021 Q1 | -6.89 Million USD | -18.34% |
| 2021 Q4 | -10.22 Million USD | 51.3% |
| 2021 Q3 | -21 Million USD | -282.55% |
| 2020 Q1 | -6.5 Million USD | -15.16% |
| 2020 Q4 | -5.82 Million USD | -0.64% |
| 2020 Q3 | -5.78 Million USD | -37.11% |
| 2020 FY | -21.91 Million USD | 24.38% |
| 2020 Q2 | -4.22 Million USD | 35.12% |
| 2019 Q3 | -7.58 Million USD | 9.5% |
| 2019 Q1 | -8.06 Million USD | -48.27% |
| 2019 FY | -28.98 Million USD | -31.13% |
| 2019 Q4 | -5.64 Million USD | 25.56% |
| 2019 Q2 | -8.38 Million USD | -3.97% |
| 2018 Q2 | -1.42 Million USD | 80.58% |
| 2018 FY | -22.1 Million USD | 10.35% |
| 2018 Q4 | -5.43 Million USD | 31.24% |
| 2018 Q3 | -7.9 Million USD | -455.41% |
| 2018 Q1 | -7.33 Million USD | -48.34% |
| 2017 Q1 | -8.21 Million USD | 0.0% |
| 2017 Q2 | -6.08 Million USD | 25.93% |
| 2017 Q3 | -5.41 Million USD | 10.93% |
| 2017 Q4 | -4.94 Million USD | 8.75% |
| 2017 FY | -24.65 Million USD | -192.76% |
| 2016 FY | -8.42 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| America Great Health | -761.42 Thousand USD | -3938.376% |
| Ampio Pharmaceuticals, Inc. | -8.63 Million USD | -256.221% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 75.225% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | -91.249% |
| Better Therapeutics, Inc. | -39.76 Million USD | 22.663% |
| Calithera Biosciences, Inc. | -18.86 Million USD | -62.986% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | -67.315% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | 14.135% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | 14.74% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 73.151% |
| Evolutionary Genomics, Inc. | -2.24 Million USD | -1267.68% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | 58.866% |
| Galera Therapeutics, Inc. | -59.08 Million USD | 47.955% |
| Innovation1 Biotech Inc. | -5.98 Million USD | -413.488% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | -44.402% |
| Molecular Templates, Inc. | -8.12 Million USD | -278.496% |
| Navidea Biopharmaceuticals, Inc. | -15.17 Million USD | -102.601% |
| NexImmune, Inc. | -32.34 Million USD | 4.933% |
| Orgenesis Inc. | -55.36 Million USD | 44.457% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | -21.716% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -39313.205% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | -68.122% |
| Scopus BioPharma Inc. | -11.6 Million USD | -164.853% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 94.632% |
| Statera Biopharma, Inc. | -174.4 Million USD | 82.37% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | -756.996% |
| Trevena, Inc. | -40.28 Million USD | 23.679% |
| Vaxxinity, Inc. | -56.93 Thousand USD | -53908.15% |
| Vaccinex, Inc. | -20.25 Million USD | -51.839% |
| Vicapsys Life Sciences, Inc. | -1.18 Million USD | -2501.192% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | 39.776% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | -295.374% |